Skip to Content

Anixa Biosciences Inc ANIX

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Anixa Biosciences Inc, a cancer-focused biotechnology company, is engaged in harnessing the body's immune system in the fight against cancer. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for early detection of solid tumors which is based on the body's immune response to the presence of a malignancy. The company also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs that genetically engineer a patient's own immune cells to fight cancer.

Contact
3150 Almaden Expressway, Suite 250
San Jose, CA, 95118
T +1 408 708-9808
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Apr 30, 2020
Fiscal Year End Oct 31, 2020
Stock Type Distressed
Employees 8